IN2015DN03235A - - Google Patents

Download PDF

Info

Publication number
IN2015DN03235A
IN2015DN03235A IN3235DEN2015A IN2015DN03235A IN 2015DN03235 A IN2015DN03235 A IN 2015DN03235A IN 3235DEN2015 A IN3235DEN2015 A IN 3235DEN2015A IN 2015DN03235 A IN2015DN03235 A IN 2015DN03235A
Authority
IN
India
Prior art keywords
benzene
membered nitrogen
optionally fused
containing heteroaryl
therapy
Prior art date
Application number
Inventor
Stephen Joseph Shuttleworth
Cyrille Davy Tomassi
Alexander Richard Liam Cecil
Somhairle Maccormick
William John Nodes
Franck Alexandre Silva
Original Assignee
Karus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1220029.1A external-priority patent/GB201220029D0/en
Priority claimed from GB201309015A external-priority patent/GB201309015D0/en
Priority claimed from GB201315254A external-priority patent/GB201315254D0/en
Application filed by Karus Therapeutics Ltd filed Critical Karus Therapeutics Ltd
Publication of IN2015DN03235A publication Critical patent/IN2015DN03235A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A compound of the formula:(I) or a pharmaceutically acceptable salt thereof, wherein: L is a 5- membered nitrogen- containing heteroaryl which is optionally fused to a benzene; Y is a 5 , 6 or 7- membered nitrogen -containing heteroaryl , which is optionally fused to a benzene; and W is a zinc- binding group. The compounds are HDAC inhibitors and therefore have potential utility in therapy.
IN3235DEN2015 2012-11-07 2013-11-06 IN2015DN03235A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1220029.1A GB201220029D0 (en) 2012-11-07 2012-11-07 Compounds
GB201309015A GB201309015D0 (en) 2013-05-20 2013-05-20 Compounds
GB201315254A GB201315254D0 (en) 2013-08-28 2013-08-28 Compounds
PCT/GB2013/052917 WO2014072714A1 (en) 2012-11-07 2013-11-06 Novel histone deacetylase inhibitors and their use in therapy

Publications (1)

Publication Number Publication Date
IN2015DN03235A true IN2015DN03235A (en) 2015-10-02

Family

ID=49585430

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3235DEN2015 IN2015DN03235A (en) 2012-11-07 2013-11-06

Country Status (11)

Country Link
US (2) US9676765B2 (en)
EP (1) EP2917202B1 (en)
JP (1) JP6329958B2 (en)
CN (1) CN104797573A (en)
AU (1) AU2013343291B2 (en)
CA (1) CA2888861A1 (en)
ES (1) ES2672701T3 (en)
IN (1) IN2015DN03235A (en)
MX (1) MX364295B (en)
NZ (1) NZ707366A (en)
WO (1) WO2014072714A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8748458B2 (en) 2009-01-28 2014-06-10 Karus Therapeutics Limited Scriptaid isosteres and their use in therapy
NZ707366A (en) * 2012-11-07 2018-11-30 Karus Therapeutics Ltd Novel histone deacetylase inhibitors and their use in therapy
AU2014264370B2 (en) 2013-05-10 2017-12-14 Karus Therapeutics Ltd Novel histone deacetylase inhibitors
MX2016016507A (en) * 2014-06-12 2017-04-27 Cedars Sinai Medical Center Compositions and methods for treating cancers.
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) * 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
WO2019139921A1 (en) 2018-01-09 2019-07-18 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
US4792562A (en) * 1985-12-04 1988-12-20 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyrrol-1-yl)pyridinamines having memory enhancing activity
JPH0532662A (en) 1990-11-09 1993-02-09 Nissan Chem Ind Ltd Substituted pyrazole derivative and agricultural and horticultural fungicide
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
WO1997040017A2 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
EP0887348A1 (en) * 1997-06-25 1998-12-30 Boehringer Mannheim Italia S.p.A. Bis-Indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them
JP3712529B2 (en) 1998-04-24 2005-11-02 大鵬薬品工業株式会社 3,3-dipyridylacrylic acid amide derivative or a pharmaceutically acceptable salt thereof
EP1793262B1 (en) 1999-02-12 2014-10-29 Hoya Corporation Spectacle lens and manufacturing method therefor
JP5278983B2 (en) 1999-11-17 2013-09-04 塩野義製薬株式会社 New uses of amide compounds
GB9929988D0 (en) 1999-12-17 2000-02-09 Celltech Therapeutics Ltd Chemical compounds
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2001083456A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
JP2004502686A (en) 2000-06-30 2004-01-29 スージェン・インコーポレーテッド 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
JP2002255964A (en) * 2000-10-24 2002-09-11 Sankyo Co Ltd Imidazopyridine derivative
AU2001295992A1 (en) * 2000-10-24 2002-05-06 Sankyo Company Limited Imidazopyridine derivatives
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
OA12790A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv New inhibitors of histone deacetylase.
JP2003313126A (en) * 2002-04-23 2003-11-06 Sankyo Co Ltd Medicine comprising imidazopyridine derivative as active ingredient
JP2004002826A (en) * 2002-04-24 2004-01-08 Sankyo Co Ltd High molecular imidazopyridine derivative
JP4235726B2 (en) * 2002-11-19 2009-03-11 国立大学法人 奈良先端科学技術大学院大学 Porphyrin chain comprising bis (imidazolyl porphyrin metal complex) linked by acetylene bonds exhibiting large two-photon absorption characteristics as a structural unit and method for producing the same
AU2003900608A0 (en) 2003-02-11 2003-02-27 Fujisawa Pharmaceutical Co., Ltd. Hdac inhibitor
JP4912145B2 (en) 2004-02-26 2012-04-11 あすか製薬株式会社 Pyrimidine derivatives
AU2005250116B2 (en) 2004-06-01 2011-01-20 F. Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor
US20090110720A1 (en) 2004-10-06 2009-04-30 Anders Nykjaer Use of compounds for the prevention of drug-induced cell toxicity
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
AU2006214319A1 (en) 2005-02-14 2006-08-24 Miikana Therapeutics, Inc. Fused heterocyclic compounds useful as inhibitors of histone deacetylase
EP1881983B1 (en) 2005-05-20 2012-01-11 Vertex Pharmaceuticals, Inc. Pyrrolopyridines useful as inhibitors of protein kinase
TW200716545A (en) * 2005-06-10 2007-05-01 Sigma Tau Ind Farmaceuti Indole derivatives having anti-tumor activity
CA2626496A1 (en) 2005-10-21 2007-05-03 Merck & Co., Inc. Potassium channel inhibitors
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
WO2007085540A1 (en) 2006-01-27 2007-08-02 Glaxo Group Limited 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
US7846929B2 (en) 2006-04-26 2010-12-07 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
BRPI0710866A2 (en) 2006-04-26 2012-08-14 Hoffmann La Roche pharmaceutical compounds
JPWO2008007780A1 (en) 2006-07-13 2009-12-10 協和発酵キリン株式会社 Pentadienamide derivatives
EP2061468A4 (en) 2006-09-11 2011-05-04 Curis Inc Tyrosine kinase inhibitors containing a zinc binding moiety
CL2007003108A1 (en) 2006-10-28 2008-07-18 Methylgene Inc Envivo Pharmace COMPOUNDS DERIVED FROM N-HYDROXYAMIDE REPLACED WITH HETEROCICLES, INHIBITORS OF HISTONE DEACETILASE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND USE TO TREAT A GROUP DISEASE THAT CONSISTS OF HUNTINGTON'S DISEASE,
JP5178731B2 (en) 2006-11-22 2013-04-10 カルス セラピューティクス リミテッド Depsipeptides and their therapeutic use
CN101663276A (en) 2007-01-31 2010-03-03 沃泰克斯药物股份有限公司 2-aminopyridine derivatives useful as kinase inhibitors
JP2010518014A (en) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド 2-Aminopyridine derivatives useful as kinase inhibitors
WO2008139987A1 (en) 2007-04-26 2008-11-20 Japan Science And Technology Agency G-protein-conjugated receptor agonist
WO2008137270A1 (en) * 2007-05-04 2008-11-13 H. Lundbeck A/S Methods of diagnosing and monitoring of npy y5 based disorders
EP2154965A4 (en) 2007-05-29 2011-08-17 Glaxosmithkline Llc Naphthyridine, derivatives as p13 kinase inhibitors
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
WO2009063240A1 (en) 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
US20110288070A1 (en) 2008-05-05 2011-11-24 ROGERS Kathryn Methods for treating cognitive disorders using inhibitors of histone deacetylase
EP2324022A1 (en) 2008-08-05 2011-05-25 Boehringer Ingelheim International GmbH Substituted naphthyridines and use thereof as medicines
EP2344490A2 (en) 2008-10-03 2011-07-20 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines active on pi3k
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US8748458B2 (en) 2009-01-28 2014-06-10 Karus Therapeutics Limited Scriptaid isosteres and their use in therapy
PL2467387T3 (en) 2009-08-20 2015-08-31 Karus Therapeutics Ltd Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors.
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
US20130227717A1 (en) 2010-10-08 2013-08-29 Life Sciences Research Partners Vzw Hdac inhibitors to treat charcot-marie-tooth disease
NZ609448A (en) 2010-12-16 2015-07-31 Hoffmann La Roche Tricyclic pi3k inhibitor compounds and methods of use
CA2825599C (en) 2011-02-01 2021-07-13 The Board Of Trustees Of The University Of Illinois 4-methyl-n-hydroxybenzamide compounds as histone deacetylase (hdac) inhibitors
EP2508510A1 (en) 2011-04-06 2012-10-10 Ikerchem, S.L. Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof
WO2013052110A1 (en) 2011-10-03 2013-04-11 The Trustees Of Columbia University In The City Of New York Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
JP6240078B2 (en) * 2011-10-04 2017-11-29 バルーク エス．ブルームバーグ インスティテュート Substituted aminothiazoles as inhibitors of cancer, including hepatocellular carcinoma, and inhibitors of hepatitis virus replication
EP2790705B1 (en) 2011-12-15 2017-12-06 Novartis AG Use of inhibitors of the activity or function of pi3k
KR101415742B1 (en) 2011-12-21 2014-07-04 영남대학교 산학협력단 6-aminopyridin-3-ol derivative or a pharmaceutically acceptable salt thereof and pharmaceutical composition for treating or preventing angiogenesis-related disease comprising the same
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
US9695108B2 (en) 2012-08-23 2017-07-04 Georgetown University Compounds and methods of use thereof for treating tumors
NZ707366A (en) 2012-11-07 2018-11-30 Karus Therapeutics Ltd Novel histone deacetylase inhibitors and their use in therapy
CN104870017B (en) 2012-11-08 2020-08-14 理森制药股份公司 Pharmaceutical composition containing PDE4 inhibitor and PI3 or dual PI 3-gamma kinase inhibitor
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
US20160052926A1 (en) 2013-03-15 2016-02-25 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
WO2014153280A1 (en) 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
AU2014264370B2 (en) 2013-05-10 2017-12-14 Karus Therapeutics Ltd Novel histone deacetylase inhibitors
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
EP3187497A4 (en) 2014-08-26 2018-02-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
GB201419228D0 (en) * 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) * 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
ES2672701T3 (en) 2018-06-15
EP2917202B1 (en) 2018-05-02
EP2917202A1 (en) 2015-09-16
MX2015005132A (en) 2015-12-07
US9676765B2 (en) 2017-06-13
US10150763B2 (en) 2018-12-11
US20180086750A1 (en) 2018-03-29
AU2013343291B2 (en) 2018-05-10
WO2014072714A1 (en) 2014-05-15
AU2013343291A1 (en) 2015-05-07
US20150361074A1 (en) 2015-12-17
JP2015535273A (en) 2015-12-10
MX364295B (en) 2019-04-22
JP6329958B2 (en) 2018-05-23
NZ707366A (en) 2018-11-30
CA2888861A1 (en) 2014-05-15
CN104797573A (en) 2015-07-22

Similar Documents

Publication Publication Date Title
IN2015DN03235A (en)
MX2016006336A (en) Pyrazolopyrimidine compounds.
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
CA2875877C (en) Syk inhibitors
RS54873B1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA030199B9 (en) Therapeutically active compounds and methods of use thereof
UA111382C2 (en) Protein kinase inhibitors
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
EA201291282A1 (en) NITROGEN-CONTAINING HETEROARRYL COMPOUNDS
EA201300200A1 (en) N - ((6-AMINOPIRIDIN-3-IL) METHYL) HETEROARILKARBOXAMIDES AS KALLYCREIN INHIBITORS IN PLASMA
MD20140072A2 (en) New pyrrole compounds, process for their preparation and pharmaceutical compositions containing them
TN2011000400A1 (en) Inhibitors of beta-secretase
EA024194B8 (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors
IN2014DN07509A (en)
MY172422A (en) Pyrazole compound and pharmaceutical use thereof
MX2017005422A (en) Diheteroaryl histone deacetylase inhibitors and their use in therapy.
MX2015017156A (en) Bace inhibitors.
NZ701933A (en) Phenoxyethyl piperidine compounds
MX364400B (en) Tetracycline compounds.
MX2017005423A (en) Polyheteroaryl histone deacetylase inhibitors and their use in therapy.
WO2012058127A3 (en) Novel compounds that are erk inhibitors
MX2015012579A (en) Azetidinyloxyphenylpyrrolidine compounds.
MX359399B (en) 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS.
PH12015501056A1 (en) 2-pyridone compound
EA201301235A1 (en) A NEW METHOD OF SYNTHESIS OF 3- (2-BROM-4,5-DIMETOXYPHENYL) PROPNANITRIL AND THE APPLICATION OF IVARBRADINE AND ITS PHARMACEUTICALLY ACCEPTABLE ACID-SALTES IN SYNTHESIS